{"id":520633,"date":"2021-07-30T07:03:16","date_gmt":"2021-07-30T11:03:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-clinical-update\/"},"modified":"2021-07-30T07:03:16","modified_gmt":"2021-07-30T11:03:16","slug":"lexicon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-clinical-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides-clinical-update\/","title":{"rendered":"Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update"},"content":{"rendered":"

\nConference Call and Webcast at 8:00 am Eastern Time
\n<\/h2>\n
\n

THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc.<\/u><\/a> (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2021 and provided an update on key milestones.<\/p>\n

\u201cWe remain on track to submit our New Drug Application (NDA) for sotagliflozin in heart failure late this year, with rising confidence in our opportunity to deliver unique value in an area of high unmet need,\u201d said Lonnel Coats, Lexicon\u2019s president and chief executive officer. \u201cOur confidence is supported by data from our SOLOIST study in patients who had recently been hospitalized for worsening heart failure and results from both our SOLOIST and SCORED studies that were consistent across the spectrum of left ventricular ejection fraction, together with the particularly acute unmet need for effective treatment options among heart failure patients in the hospitalization setting and in the large population of patients with normal, or \u201cpreserved,\u201d left ventricular ejection fraction (\u2265 50%). We are further encouraged by the feedback from our recently-completed pre-NDA meeting with the FDA and are accelerating our efforts to prepare for a commercial launch in what we believe will be a rapidly growing market served by a concentrated prescriber base.\u201d<\/p>\n

\u201cWe have seen a meaningful pick-up in enrollment in our two Phase 2 proof-of-concept studies of LX9211 in neuropathic pain while maintaining as a priority the importance of proper patient selection that is built into the study design,\u201d continued Mr. Coats. \u201cOur mitigation efforts have begun to take effect and the COVID-19 environment has improved relative to earlier this year, but not enough to achieve top-line results by year-end. We now expect to have top-line results from these studies in the first half of 2022.\u201d<\/p>\n

\n
\n Second Quarter Highlights<\/u>
\n <\/strong>\n <\/p>\n

\n Sotagliflozin<\/strong>\n <\/p>\n